



















































































































































disorders,  the  tissue  sweeper  function  of  metformin  may  inhibit  the  malignant/metastatic  progression  of  pre‐
malignant/senescent tumor cells and increase the human lifespan.  
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fundamental for adequate protection from develop-
mental defects, cancer, and aging. Central to this 
process is the ability of cells to accurately recognize and 
correctly repair DNA damage in a timely manner to 
then allow regulated and orderly progression through 
the cell cycle. By linking genome stability surveillance, 
cell cycle, and energy metabolism, the ∼370 kDa Serine 
(Ser)/Threonine (Thr) kinase ataxia telangiectasia 
mutated (ATM) has begun to emerge as a central DNA 
damage checkpoint that connects cellular bioenergetics 
with cancer predisposition and aging [1-4]. ATM is a 
member of the phosphoinositide 3-kinase-related 
protein kinase (PIKK) family to which the master 
regulator of cell growth and metabolism mammalian 
target of Rapamycin (mTOR) also belongs [5]. ATM is 
a well-known primary regulator of the cellular response 
to DNA double-strand breaks (DSBs). A number of 
studies have recently established that oxidative stress also 
activates ATM, even in the absence of DSBs. In response 
to oxidative stress, ATM is phosphorylated at Ser-1981, 
which results in phosphorylation of its substrates, 
including p53, the master controller of DNA metabolic 
stresses, and AMP-activated protein kinase-α (AMPKα), 
the key sensor of fuel and energy status [6, 7]. 
 
ATM: Connecting the energy restriction mimetic 
metformin to its metabolic target AMPK. Energetic 
stress due to glucose restriction increases the AMP/ATP 
ratio. Treatments with drugs that increase the 
AMP/ATP ratio, including the AMP analog 5-
aminoimidazole-4-carboxamide-1-β-ribofuranoside 
(AICAR) or the anti-diabetic biguanide metformin, 
activate AMPKα through phosphorylation of Thr-172 
and also increase the levels of the AMPKα protein. 
Although several proteins can phosphorylate AMPKα 
(e.g., the master upstream Ser/Thr kinase 11 
(STK11)/Liver Kinase B1 [LKB1]), it should be noted 
that activating phosphorylation of AMPKα in response 
to energetic stress takes place in an ATM-dependent 
and STK11/LKB1-independent manner [7]. 
Accordingly, the selective ATM inhibitor KU-55933 
markedly reduces the AMPKα-activating effects of 
metformin in rat hepatoma cells, functionally 
supporting the first genome-wide association study that 
unexpectedly found the ATM gene as the causal 
modulator of glycemic responsiveness to metformin 
among type 2 diabetic patients [8]. Indeed, treatment 
with the ATM inhibitor KU-55933 is sufficient to 
prevent metformin-induced phosphorylation of AMPKα 
and of the AMPKα downstream target Acetyl-CoA 
Carboxylase (ACC), concluding that ATM works 
upstream of AMPKα and that ATM is required for a 
full response to metformin [8]. Although these results 
support and extend previous reports of ATM 
involvement in the activation of AMPKα by stimuli 
other than metformin [7, 9, 10], metformin’s ability to 
function as a general activator of the ATM-dependent 
DDR pathway remains to be explored to prove a causal 
link between the metformin-induced activation of ATM 
and the diminished risk of developing cancer in 
individuals taking this drug [11].  
 
We have recently added metformin to the growing list 
of agents that may have potent cancer-preventive 
properties by activating the ATM-regulated DDR 
pathway [12]. The treatment of cultured tumor cells 
with millimolar concentrations of metformin was found 
to promote significant activation of ATM, as 
determined by immunofluorescence microscopy using a 
monoclonal antibody directed against Ser-1981-
phosphorylated ATM. Because cellular DNA damage 
and particularly the induction of DSBs result in 
activating phosphorylation of ATM at Ser-1981 and 
Histone H2AX at Ser-139, we also explored whether 
the Ser-139 Histone H2AX phosphorylation was altered 
in response to metformin. Metformin-induced induction 
of phospho-γH2AX
Ser139 foci was not accompanied by 
the expected incorporation of 53BP1 to nuclear repair 
foci, and metformin-induced Ser-1981 ATM 
phosphorylation displayed a uniform, nuclear signal that 
failed to colocalize with phospho-γH2AX
Ser139 foci. 
Thus, we termed these metformin-triggered events 
“pseudo-DDR”  [13] to distinguish them from a bona 
fide DDR triggered in response to true DNA damage. 
Importantly, “metformin-induced pseudo-DDR” was 
accompanied by the activation of functional elements 
typically involved in ATM-regulated genomic stress. 
First, metformin treatment greatly enhanced phospho-
rylation of Chk2 at Thr-68, an ATM kinase-dependent 
event that mediates the response of the ATM pathway 
following DNA damage [14, 15]. Second, metformin 
exposure notably enhanced phosphorylation of cAMP-
Response Element Binding protein (CREB) at Ser-133, 
an ATM kinase-regulated event in response to oxidative 
DNA damage and DNA replication stress [16, 17].  
 
Metformin and ATM-sensed energy metabolism: 
Reactivating oxidative phosphorylation biogenesis to 
impede glycolytic cancer cell growth.  As metformin 
is thought to activate AMPK by inhibiting oxidative 
phosphorylation [18, 19] and because phosphorylation 
of CREB at Ser-133 can be observed in cultured cells 
that have been incubated with oxidative phospho-
rylation inhibitors [20], it could be argued that 
metformin-induced CREB activation might merely 
reflect metformin’s ability to impair mitochondrial 
activity in tumor cells. However, CREB 
phosphorylation is pivotal in mediating peroxisome 
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1alpha (PGC-1α)-stimulated mitochondrial biogenesis 
[21-24]. Therefore, metformin-stimulated phosphoryla-
tion of CREB at Ser-133, which activates the promoter 
of PGC-1α and increases PGC-α mRNA and protein 
expression [25, 26], can also be viewed as part of the 
mechanism through which metformin may control 
mitochondrial biogenesis in tumor cells. Tumor cells are 
dependent on glycolysis to support their metabolic 
requirements; even under aerobic conditions, tumor 
cells continue to rely on glycolysis rather than oxidative 
phosphorylation (Warburg effect), resulting in high 
glucose requirements to generate energy and 
biosynthetic precursors because of the increased 
availability of glycolytic intermediates [27-30]. As 
such, metformin-induced reactivation of oxidative 
phosphorylation biogenesis may contribute to the 
growth arrest of cancer cells. A recently developed 
high-throughput respirometric assay for mitochondrial 
biogenesis used the Seahorse Bioscience analyzer to 
measure mitochondrial function in real time. In adapted 
primary cultures of non-glycolytic renal proximal 
tubular cells, metformin augmented mitochondrial 
biogenesis [31]. Recent experiments from our own 
laboratory have established that culturing human cancer 
cells in the presence of metformin significantly 
enhances the expression of cytochrome c oxidase I 
(COX-1) and mitochondrial succinate dehydrogenase 
(SDH-A), which are encoded by mitochondrial and 
nuclear genomes, respectively (Oliveras-Ferraros C, 
Cufí S, Vazquez-Martin A, Menendez OJ, Martin-
Castillo B, Joven J, Menendez JA. Metformin rescues 
cell surface major histocompatibility complex class I 
deficiency caused by oncogenic transformation. 
Submitted for publication). Using cancer cell lines, non-
cancer cells, embryonic cells and Rho(0) cells (i.e., cells 
depleted of mitochondrial DNA), Jose et al. [32] 
recently confirmed that the AMPK agonist AICAR 
exhibits a strong and cancer-specific growth effect that 
depends on the bioenergetic signature of the cells and 
involves upregulation of oxidative phosphorylation. In 
fact, the sensitivity to pharmacological activation of 
AMPK is higher when cells display a high proliferation 
rate accompanied by a low steady-state content of ATP. 
Although it remains to be established if AMPKα-related 
induction of mitochondrial biogenesis to increase 
oxidative phosphorylation is instrumental and possibly 
required for the anti-cancer/anti-aging effects of 
metformin [33, 34], it is becoming clear that some 
health-promoting capabilities of metformin may rely on 
its ability to function as a bona fide glucose-starvation 
mimetic. Accordingly, recent experiments from our own 
laboratory have confirmed that, when added to glucose-
free medium, where growth is highly oxidative 
phosphorylation-dependent, metformin drastically 
increases apoptotic cell death in glucose-addicted 
cancer cell cultures. Because transformed human cell 
types appear to be more sensitive to glucose 
deprivation-induced cytotoxicity and metabolic 
oxidative stress than non-transformed human cell types, 
we suggest that a rational use of metformin in 
combination with fasting could significantly potentiate 
the effects of chemotherapy in cancer while protecting 
normal cells, thus further increasing the therapeutic 
window [35-38] (Oliveras-Ferraros C, Cufí S, Vazquez-
Martin A, Menendez OJ, Joven J, Martin-Castillo B, 
Menendez JA. Glucose deprivation enhances 
metformin-induced apoptosis in a breast cancer cell 
type-dependent manner: Implications for cyclotherapy. 
Manuscript in preparation).  
 
In the last issue of Aging, Halicka et al. [39] reported 
that treatment of normal mitogenically stimulated 
lymphocytes or tumor cell lines treated with metformin 
attenuated ATM activation and constitutive H2AX 
phosphorylation. Their observation that cells treated 
with metformin have reduced expression of Ser-1981-
phosphorylated ATM and Ser-139-phosphorylated 
Histone H2AX is in contrast not only to data previously 
reported by our own group in Cell Cycle [12] but also to 
those presented by Dian et al. [40] in a recent issue of 
PLoS One. Using human diploid fibroblasts (HDFs), 
these authors reported that treatment with 
pharmacological agents increasing the AMP/ATP ratio 
(i.e., AICAR and metformin) is molecularly equivalent 
to the effects of glucose restriction in terms of 
activation of the ATM/AMPK pathway. On one hand, 
glucose restriction-induced activation of AMPK-driven 
intracellular signaling was found to be an ATM-
dependent process. Thus, the ability of glucose 
restriction to increase the activating phosphorylation of 
AMPKα cannot be observed in ataxia-telangiectasia (A-
T) cells. On the other hand, treatment of HDFs with the 
AMPK agonists AICAR or metformin activates ATM at 
Ser-1981, increases the overall levels of ATM protein 
and activates AMPK [40]. These findings together 
indicate that the energetic stress that is induced by 
glucose restriction or metformin treatment can activate 
the ATM/AMPKα pathway to induce autophagy and 
likely cellular senescence. These observations are 
consistent with the idea that disruption of an energetic 
stress-induced checkpoint through the loss of ATM 
function may provide a growth advantage to cells under 
energetic stress but exacerbate cytotoxic responses to 
metformin [41].  
 
We recently hypothesized that the unexpected ability of 
metformin to promote the activation of ATM may be 
due to the short (24 or 48 h) time courses of most 
published studies on metformin-induced energetic stress 
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hypothesis and to simulate patients receiving metformin 
on a daily basis, we maintained A431 epidermoid 
cancer cells in long-term uninterrupted subculture with 
metformin concentrations as high as 10 mmol/L for 
longer than 4 months before starting any experimental 
procedure. Metformin-induced loss of proliferative 
potential, as measured by the absence of immuno-
reactive Histone H3 phosphorylated at Ser-10 (Figure 
1A), was accompanied by chronic activation of 
autophagy, as measured by confocal imaging of the 
recruitment of ATG8/LC3 to autophagic vesicles (“LC3 
puncta”) and loss of the specific autophagy receptor 
p62/SQSTM1, a protein that is selectively degraded by 
autophagy (Figure 1B) [42]. Of note, growth 
retardation and subsequent arrest of A431 tumor cells 
in response to the chronic energetic stress imposed by 
continuous exposure to metformin drastically up-
regulated ATM activity and ATM protein 
accumulation. Indeed, fluorescence microscopic 
analyses revealed a massive accumulation of a 
uniform, nuclear signal of both total ATM (Figure 2A) 
and Ser-1981 phosphorylated ATM (Figure 2B). 
Furthermore, A431 cells chronically treated with 
metformin displayed flattened, giant, polynucleated 
morphology (Figure 2C). These findings not only 
reaffirm our earlier results and those reported by Duan 
et al. [40] on metformin-induced activation of the 
ATM/AMPKα pathway, but they additionally suggest 
that metformin-mimicked glucose restriction appears 
to reactivate the senescence program in cancer cells 
(Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, 
Martin-Castillo B, Vellon L, Menendez JA. Metformin 
lowers the threshold for stress-induced cellular 
senescence. Manuscript in preparation). 
 
The above mentioned data suggest an attractive 
complementary strategy by which we might prevent or 
halt cancer that is functionally compatible with 
activation of the ATM pathway: the senescence process 
is dependent on ATM signaling, and senescence can be 
bypassed or suppressed by microinjection of kinase-
dead constructs of ATM or by treatment with ATM 
inhibitors [42-46]. Metformin-treated A431 cell cultures 
typically revealed senescent cells with a damaged 
nucleus that, in some cases, appeared to evolve through 
progressive encircling of the nucleus by refringent 
components. Numerous dense particles (probably 
damaged components) and several autophagic vacuole-
like structures of different sizes were observed within 
large cells displaying multiple nuclei, micronucleation, 
or lobulated nuclei. Chronic exposure of cancer cells to 
metformin might provoke permanent senescent-cell 
growth arrest as a result of a high macroautophagic 












































cancer cell components. This supports earlier studies 
demonstrating that, in contrast to the widely accepted 
antioxidant properties of the anti-aging polyphenol 
resveratrol, chronic culture of cancer cells with 
resveratrol initiates replication stress via activation of 
the ATM pathway and induces senescence associated 
with mitochondria-increased reactive oxygen species 
(ROS) levels [47]. This report and our current findings 
appear to functionally link the cell cycle with pro-
oxidant/pro-senescent effects of anti-aging compounds 
in cancer cells [39]. In contrast, Halicka et al. found that 
the anti-oxidant activity of metformin is functionally 
 
Figure  1.  Chronic  exposure  to  metformin  suppresses  the
proliferative activity of human [A431] cancer cells (A) to enter
a  form  of  permanent  cell‐cycle  arrest  accompanied  by  the
induction of “self‐digesting” autophagy (B).  
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of action underlying the anti-aging effects of 
metformin. At present, we cannot explain the apparent 
discrepancy of our results [12] and those of Duan et al. 
[40] with the data presented by Halicka et al. [39]. 
These contradictory hypotheses must be tested 
adequately before concluding the ultimate mechanism 
by which metformin exerts anti-cancer and/or anti-
aging effects.  
 
Metformin accelerates the onset of cellular senescence 
in human diploid fibroblasts (HDFs). The onset of 
cellular senescence is thought to protect against the 
initiation of tumor formation in response to certain 
cellular stresses, including genotoxic and energetic 
stresses [48]. Environmental factors that place oxidative 
stress on cells promote the early onset of cellular 
senescence by significantly increasing the AMP/ATP 
ratio and activating stress pathways involving AMPK 
[49]. AMP/ATP ratios are significantly higher in 
senescent fibroblasts compared with young fibroblasts 
and, accordingly, in vitro senescence is accompanied by 
a marked elevation of AMPK activity. Indeed, ATP 
depletion in senescent fibroblasts is due to the 
dysregulation of glycolytic enzymes and a failure to 
maintain ATP levels, which finally leads to a drastic 
increase in cellular AMP. This, in turn, acts as a 




























nescence [50]. Within this model, escaping fromcellular 
senescence and becoming immortal constitutes a crucial 
step in oncogenesis that most tumors require for 
ongoing proliferation [51].  
 
The cumulative oxidative damage induced by growth in 
conditions that are hyperoxic (by the standard of living 
tissues) leads to the onset of senescence in HDFs and 
mouse embryo fibroblasts (MEFs). Indeed, when 
HDFs/MEFs are propagated in hypoxic conditions (1-
3%) rather than the commonly used 20% oxygen, 
HDFs/MEFs avoid senescence; when grown in 20% 
oxygen, HDFs/MEFs rapidly accumulate DNA damage 
and eventually initiate a positive feedback loop of 
oxidative damage and growth arrest that masquerades as 
cellular senescence [51, 52]. Immortalized MEFs and 
mouse/human embryonic stem cells display higher 
glycolytic flux with reduced oxygen consumption and 
therefore present more resistance to oxidative damage 
than senescent cells. As such, they demonstrate the 
Warburg effect (enhanced glycolysis), which plays a 
causative role in cell immortality by protecting cells 
from senescence induced by oxidative damage [53-56]. 
Thus, it can be speculated that exogenous supplemen-
tation with metformin should increase the population-
doubling potential of cultured HDFs and MEFs by 
preventing the accumulation of ROS and oxidative 




























Figure  2.  Chronic  exposure  to  metformin
activates the DNA damage sensor kinase ATM in
poly‐morphic,  polyploidy  [A431]  cancer  cells















































Conversely, recent experiments conducted in our 
laboratory have concluded that chronic exposure to 
millimolar concentrations of metformin (1 and 10 
mmol/L) drastically reduces the lifespan of non-
transformed HDFs by accelerating replicative cellular 
senescence (Figure 3A). Indeed, metformin exposure 
reduced cumulative population doublings by up to 70% 
in HDFs (Cufí S, Vazquez-Martin A, Oliveras-Ferraros 
C, Martin-Castillo B, Vellon L, Menendez JA. 
Metformin lowers the threshold for stress-induced 
cellular senescence. Manuscript in preparation). 
Metformin’s ability to accelerate the onset of replicative 
senescence was more significant in WI-38 fetal lung 










































mature senescence [57]. BJ-1 fibroblasts required 
longer exposures to higher concentrations of metformin, 
as they are extremely resistant to hyperoxia and H2O2 
[58, 59]. Although we did not explore the activation 
status of ATM in HDFs chronically exposed to 
metformin, it is reasonable to conclude that the 
metformin-lowered threshold for stress-induced 
senescence must be explained in terms of metformin-
augmented oxidative damage in HDFs. In other words, 
metformin-accelerated replicative senescence might 
mostly rely on metformin’s ability to establish a 
stronger DDR-dependent cell cycle arrest because 
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damage and cellular senescence in cultured HDFs.  
 
2. Metformin sensitizes HDFs and cancer cells to 
DSB-induced cellular senescence. Doxorubicin is an 
anthracycline that indirectly causes DSBs, activates 
ATM-dependent signaling, and induces cell senescence 
at concentrations significantly lower than those required 
to induce apoptotic cell death. Treatment of cells with 
doxorubicin leads to the phosphorylation of Histone 
H2AX on Ser-139, with dependence on ATM for the 
initial response [60]. Treatment with doxorubicin also 
stimulates ATM autophosphorylation on Ser-1981 and 
the ATM-dependent phosphorylation of numerous 
effectors in the ATM-signaling pathway, including 
Chk2, in a ROS-dependent manner [60]. Because free 
radical scavengers have been shown to attenuate the 
accelerated senescence response triggered by treatment 
with a low concentration of doxorubicin in MCF-7 
breast cancer cells [61-63], Halicka’s hypothesis that 
metformin acts as an anti-oxidant that enhances genome 
stability via ATM inhibition [39] would dictate that 
metformin treatment must efficiently block 
doxorubicin-induced senescence [64]. We recently 
assessed whether metformin treatment can regulate the 
senescence-like growth arrest induced by doxorubicin in 
primary MEFs from wild-type (p53
+/+) mice. Of note, 
exposure of MEFs to millimolar concentrations of 
metformin (1 and 10 mmol/L) augmented baseline 
senescence in doxorubicin-untreated control cultures 
and notably potentiated cell senescence triggered by 
doxorubicin-induced DNA damage (Cufí S, Vazquez-
Martin A, Oliveras-Ferraros C, Martin-Castillo B, 
Vellon L, Menendez JA. Metformin lowers the 
threshold for stress-induced cellular senescence. 
Manuscript in preparation). Furthermore, we 
maintained MCF-7 breast cancer cells (wild-type p53) 
in long-term uninterrupted subculture with metformin 
concentrations as high as 10 mmol/L for longer than 4 
months and then challenged them with a senescence-
inducing concentration of doxorubicin. Interestingly, 
the pre-conditioned MCF-7 cells became sensitized to 
senescence induction by low doses of doxorubicin 
(Figure 3B). We observed that sequential incubation 
with metformin, followed by 100 nmol/L of 
doxorubicin, produced a drastic change in the cellular 
response program. In response to doxorubicin-induced 
stress, wild-type MCF-7 cells showed low levels of SA-
β-gal positive cells (~15%), and MCF-7/Metformin 
cells showed very high levels (~54%). This indicated a 
senescent-like phenotype without signs of apoptotic cell 
death. By activating AMPK, metformin treatment 
appears to induce a sensitizing stress that creates a 
metabolic cellular imbalance in favor of the pro-
senescent effects induced by DNA damaging agents. 
Metformin’s ability to accelerate the onset of cellular 
senescence in HDFs and enhance DNA damage-induced 
senescence might provide a rational approach to 
sensitizing pre-malignant and cancer cells to further 
stress induced by oncogenic stimuli.  
 
3. Metformin impedes nuclear reprogramming of 
somatic cells to induced Pluripotent Stem Cells 
(iPSCs).  Somatic cells can be reprogrammed by the 
expression of four factors associated with pluripotency, 
the so-called “Yamanaka factors” OSKM (O = OCT4, S 
= SOX2, K = KLF4, M = and c-MYC) [65]. Several 
groups have observed that a DDR compatible with 
DNA replication-induced DNA damage is mounted 
upon the expression of the OSKM reprogramming 
factors [66-68]. This appears to be similar to what 
occurs during oncogene-induced senescence (OIS), 
when cell proliferation and transformation induced by 
oncogene activation in early tumorigenesis is restrained 
by cellular senescence, which results from the ATM-
mediated DDR triggered by oncogene-induced DNA 
hyper-replication [69, 70]. However, it should be noted 
that expression of the four Yamanaka factors has been 
shown to result in the accumulation of 8-oxoguanine 
adducts in human fibroblasts, which are commonly the 
result of oxidative stress. Furthermore, c-MYC 
overexpression induces DNA damage in a mainly ROS-
dependent rather than DNA replication-dependent 
manner [71, 72]. Therefore, the DNA damage occurring 
upon reprogramming may be caused not only by 
OSKM-driven aberrant replication but also through the 
generation of ROS, which can explain why 
reprogramming is significantly more efficient under 
either low oxygen conditions or in the presence of anti-
oxidants such as vitamin C [73-76]. Vitamin C 
efficiently alleviates reprogramming-induced sense-
cence (RIS) [66, 75-77], suggesting that antioxidants or 
other compounds that transiently inhibit senescence 
could be used to improve reprogramming efficiency. As 
such, the interplay between the expression of 
reprogramming factors and the activation of a p53-
mediated [68, 78] DDR due to increased DNA 
replication and/or ROS creates a model in which to test 
the anti-oxidant (Halicka’s findings [39]) or pro-
senescent (Vazquez-Martin’s findings [12]) effects of 
metformin in terms of enhanced or repressed 
reprogramming efficiency, respectively. Because 
reprogramming in the presence of pre-existing, but 
tolerated, DNA damage is aborted by the activation of 
DDR- and p53-dependent apoptosis [68], metformin’s 
ability to reduce ATM activity should attenuate the p53 
response to DNA damage (as in some preneoplastic 
lesions [79, 80]), resulting in accelerated somatic 
reprogramming. Using MEFs or mouse adult fibroblasts 
(MAFs), we recently tested the effect of metformin in 
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with metformin dose-dependently inhibited somatic cell 
reprogramming induced by the OSK stemness factors in 
MEFs. At 10 mmol/L metformin, iPSC formation was 
virtually undetectable in MEFs and in MAFs (Vazquez-
Martin, Vellon L, Cufi S, Oliveras-Ferraros C, Quirós 
PM, Lopez-Otin C, Javier A. Menendez. Metformin 
impedes reprogramming of somatic cells into stem cells. 
Manuscript in preparation). Parallel experiments 
performed with human BJ-1 fibroblasts transduced with 
OSKM reprogramming factors produced effects similar 
to metformin in drastically inhibiting reprogramming 
(Vazquez-Martin, Vellon L, Cufi S, Oliveras-Ferraros C, 
Quirós PM, Lopez-Otin C, Javier A. Menendez. 
Metformin impedes reprogramming of somatic cells into 
stem cells). Manuscript in preparation). Because p53-
mediated DDR limits reprogramming to ensure iPSC 
genomic integrity [68], it could be argued that these 
findings are consistent with a genome-protective effect of 
metformin, which in turn can reduce DNA replication 
stress [39]. However, metformin exposure was found to 
abolish highly efficient reprogramming upon abrogation 
of p53 in MAFs. Importantly, the observed effects on 
reprogramming efficiencies were not due to metformin-
induced cell death of the starting somatic population but 
rather to the metabolic, pro-senescent effects exerted via 
AMPK activation [81, 82]. When metformin, which 
indirectly activates AMPK through effects on the 
mitochondria, was replaced with the small-molecule A-
769662, which directly activates AMPK by mimicking 
both effects of AMP, including allosteric activation and 
inhibition of dephosphorylation [83-86], reprogram-
ming efficiency was also drastically reduced.  
 
Recent studies have indicated that somatic cells convert 
from an oxidative to glycolytic state when they are 
reprogrammed [87-90] and that the bioenergetic states 
of somatic cells appear to correlate with their 
reprogramming efficiencies. Furthermore, manipulating 
these bioenergetic changes can affect reprogramming, 
as the glycolysis inhibitor 2-deoxy-D-glucose [2-DG] 
decreases reprogramming, whereas the glycolysis 
stimulator D-fructose-6-phosphate (F6P) increases 
reprogramming of fibroblasts [89, 90]. Although further 
studies aimed at dissecting the exact mechanism of 
metformin action in regulating somatic cell 
reprogramming are needed, it is reasonable to suggest 
that impaired reprogramming following metformin 
treatment might result from compromised glycolysis 
and energy crisis, leading to the sustained activation of 
AMPK and the establishment of a senescent phenotype, 
a crucial roadblock for reprogramming [66, 75].  
 
Metformin and cancer: Hastening the onset of 
stress-induced senescence to enhance protection 
against cancer. Understanding the metabolic changes 
associated with somatic cell reprogramming might shed 
light on the “metabolic transformation” that is required 
to support not only the increased biosynthetic needs of 
the tumor cell but also to enable the acquisition of 
stemness properties in cancer stem cells (CSCs). Many 
of the changes in cell metabolism that have been 
identified to be important in regulating somatic cell 
reprogramming and induced pluripotency also play 
roles in oncogenesis. On the other hand, reprogramming 
to a more dedifferentiated state occurs during tumor 
progression (i.e., the activation of an embryonic stem 
cell-like transcriptional program in differentiated adult 
cells may induce pathologic self-renewal/stemness 
characteristics of CSCs [91]) and might be favored by 
alterations in crucial tumor suppressors. Indeed, the 
stress mechanisms triggered by expression of the 
Yamanaka stemness factors, which ultimately lead to 
reprogramming, elicit the tumor suppressor pathways 
that naturally protect cells against the uncontrolled 
growth that occurs during tumorigenesis. 
Unsurprisingly, the cellular response to expression of 
the reprogramming factors or stem-cell-specific genes 
molecularly mimics the senescence response observed 
during OIS, thus emphasizing the parallels between RIS 
and OIS. In this scenario, if metformin treatment 
appears to reinforce RIS in somatic reprogramming 
experiments, we can then infer that metformin treatment 
should improve cells’ ability to establish a more 
efficient senescence response in pre-malignant and 
malignant tissues. Many tumor cells appear to have 
developed mechanisms to reduce AMPK activation and 
therefore escape from its growth-arrest and tumor-
suppressor effects. In fact, more aggressive tumors 
exhibit reduced signaling via the AMPK pathway, and 
an inverse relationship exists between the AMPK 
activation status with histological grade and metastasis 
[92-94]. As such, metformin-induced energy crisis and, 
therefore, AMPK (re-)activation, may functionally 
disrupt the deleterious connection between pluripotency 
and oncogenic transformation. In fact, Struhl’s team 
discovered that metformin treatment can selectively kill 
the chemotherapy-resistant subpopulation of CSCs in 
genetically distinct types of breast cancer cell lines [95, 
96]. Our own group has confirmed that treatment with 
metformin can suppress the self-renewal and 
proliferation of cancer stem/progenitor cells in HER2 
gene-amplified breast carcinomas cells refractory to 
HER2-targeted drugs [97, 98]. The central mechanisms 
through which metformin exposure blocks the 
ontogenesis of the CSC molecular signature have begun 
to be elucidated in cultured cancer cells, including 
alterations of epithelial-to-mesenchymal transition 
drivers/effectors, tumor-suppressor miRNAs and 
oncomiRs [99-101]. Metformin’s ability to oppose 
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oxidative mitochondria toward an alternative ATP-
generating glycolytic metabotype may be sufficient to 
inhibit the network required for the establishment and 
maintenance of stem cell pluripotency and self-renewal 
imposed by certain oncogenic stimuli in the right 
cellular context [102].  
 
Recently, evidence has emerged that the DDR is one of 
the earliest events that impedes the multistep 
progression of human epithelial carcinomas to invasive 
malignancy. DNA damage can be due to a variety of 
factors, such as telomere dysfunction or oncogene-
induced replication stress [103-105]. Consequently, 
there is a strong selective pressure for mutation in DDR 
components because DNA damage checkpoints act as 
native blockades against the acquisition of 
invasive/metastatic properties during malignant 
transformation [103, 105]. Epithelial cells within pre-
malignant lesions with markers of senescence maintain 
an intact response to cellular stress and are less likely to 
develop subsequent tumors. Accordingly, the presence 
of functional pro-senescence mechanisms is the most 
accurate predictor of recurrence and progression of 
premalignant lesions in situ (e.g., in ductal carcinoma in 
situ [DCIS] of the breast) to biologically aggressive 
invasive carcinomas (e.g., basal-like breast carcinomas) 
[106]. Because the DDR is the major innate tumor 
suppressor barrier in early human tumorigenesis, 
selective activation of DDR surveillance mechanisms 
may therefore directly contribute to metformin’s cancer 
preventive effects. Proliferative invasive cancer cells 
with activated oncogenes acquire mechanisms to 
suppress senescence in the early stages of cancer 
pathogenesis (e.g., in situ lesions). Organisms in which 
cells fail to undergo senescence die prematurely of 
cancer [107]. Therefore, activating the program of 
senescence in tumor cells is an attractive approach to 
cancer treatment [108, 109] and may help to explain the 
differential impact of metformin on cancer incidence in 
non-prone and cancer-prone animal models and perhaps 
also in cancer-prone individuals. It remains to be clearly 
defined whether metformin’s ability to strongly activate 
the ATM-regulated DDR checkpoint is the critical event 
that prevents neoplastic epithelium from progressing 
unimpeded into invasive cancer in individuals without 
type 2 diabetes. However, reduced cancer risk in type 2 
diabetic patients taking metformin can be explained in 
terms of metformin’s ability to activate DNA damage-
like signaling that induces specific senescence-like 
growth inhibition of pre-malignant or malignant cells 
without altering the normal function of non-neoplastic 
tissues. We are currently developing a pre-clinical 
framework for pro-senescence, metformin-based anti-
cancer therapies by evaluating metformin’s effects on 
DCIS xenografts during their spontaneous transition to 
invasive cancer lesions [110-112]. It would also be 
relevant to evaluate whether metformin facilitates the 
“accelerated senescence” triggered in normal cells by 
the expression of mutated, transforming versions of 
oncogenes (e.g., Ras or Raf) and by some other forms of 
supraphysiological mitogenic signaling irrespective of 
senescence-inhibiting adaptations (e.g., inactivation of 
p53) [69, 113, 114]. In a clinical scenario, it would be 
interesting to test whether metformin can significantly 
increase senescence in premalignant lesions of the skin, 
the lung, the pancreas, the liver or the breast. 
Additionally, forthcoming studies should evaluate 
metformin’s effects in clinical scenarios in which 
senescence has been recognized to have positive effects 
on organ maintenance. Senescence limits pathological 
responses to either acute forms of injury such as fibrotic 
scarring in response to chemically induced liver injury 
[98, 115, 116] or to chronic viral infections such as 
hepatitis C virus (HCV) with or without concomitant 
human immunodeficiency virus (HIV) infection. 
Indeed, HCV infection increases rates of hepatocellular 
carcinoma via the accumulation of senescent 
hepatocytes in human liver [117].  
 
Metformin: Lowering the threshold for stress-
induced senescence to limit cancer development and 
delay aging-associated disorders. Metformin’s ability 
to enhance senescence in established premalignant 
disease or in fully malignant disease is a largely 
unexplored mechanism that may explain why reductions 
in cancer mortality related to metformin use are similar 
in magnitude to reductions in cancer incidence. This 
suggests that the anti-cancer effects of metformin 
largely depend on (or are restricted to) its preventive 
effects [118]. The most widely accepted interpretation 
for the biological function of cellular senescence is that 
it serves as a mechanism for restricting cancer 
progression. Based on this, escaping from cellular 
senescence and becoming immortal constitute a 
required additional step in the progression of 
oncogenesis [51, 52]. Recent studies have suggested 
that the accumulation of ROS and oxidative damage are 
commonly involved in culture stress- or oncogene-
induced cellular senescence. Increasing accumulation of 
ROS is observed during replicative senescence, and the 
replicative potential of MEFs and HDFs is significantly 
higher under low oxygen conditions. As such, the 
ability of immortalized cells, including embryonic stem 
cells (ESCs), iPSCs and CSCs, to buffer oxidative stress 
may be pivotal for explaining their immortality [53-56; 
87-90]. Enhanced glycolysis actively protects cells from 
senescence induced by oxidative stress [53-56], a 
metabolic protection that appears to causally contribute 
to the maintenance of the self-renewal capacity of stem 
   
www.impactaging.com                1071                                  AGING, November 2011, Vol.3 No.11cells [87-90]. In fact, the enhanced glycolysis of the 
Warburg effect is a crucial metabolic feature that helps 
cancer cells bypass senescence, and this may provide 
indirect evidence that metformin’s primary target is the 
immortalizing step during tumorigenesis. In other 
words, if enhanced glycolysis is necessary and 
sufficient to enable indefinite proliferation (i.e., 
immortalization) very early during multi-step 
carcinogenesis  in vivo, then metformin’s ability to 
inhibit glucose flux while simultaneously stimulating 
lactate/pyruvate flux and mitochondrial biogenesis must 
cause ATP depletion accompanied by a drastic increase 
in cellular AMP, which is expected to induce premature 
senescence [50]. Many tumor cells retain the ability to 
senesce in response to DNA-damaging drugs in culture 
and  in vivo. Because of this, metformin-accelerated 
replicative senescence due to a stronger DDR-
dependent cell cycle arrest may underlie metformin’s 
ability to increase the rate of pathological complete 
response (pCR) in neoadjuvant chemotherapy in 
diabetic patients with breast cancer [119] and to 
promote tumor regression and prevent relapse when 
combined with suboptimal doses of chemotherapy in 
animal models [96].  
 
Senescent cells accumulate in various tissues and 
organs with aging and have been hypothesized to 
disrupt tissue structure and function [120-122]. Cellular 
senescence halts the proliferation of damaged or 
dysfunctional cells, thus functioning as a pivotal 
mechanism to constrain the malignant progression of 
tumor cells [123, 124]. Indeed, upon the aberrant 
activation of oncogenes, normal cells can enter the 
cellular senescence program, a state of stable cell-cycle 
arrest that represents an important barrier against tumor 
development  in vivo [125]. Senescent cells 
communicate with their environment by secreting 
various cytokines and growth factors, and this 
“secretory phenotype” has been reported to have pro- as 
well as anti-tumorigenic effects [126-130]. In this 
regard, it is remarkable that metformin-induced chronic 
activation of ATM signaling in A431 epidermoid cancer 
cells is accompanied by the increased expression of a 
wide variety of cyto-/chemokines (e.g., IL6, IL1B, 
CCL3, CCL5, IL1F9 or CXCL11), as measured by 
Agilent’s whole human genome arrays (Figure 3C) 
(Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, 
Martin-Castillo B, Vellon L, Menendez JA. Metformin 
lowers the threshold for stress-induced cellular 
senescence.  Manuscript in preparation). Cellular 
senescence is often the result of ATM sensing of 
nuclear DNA damage fueling chronic DDR, and 
upstream elements of the DDR signaling cascade are 
necessary to successfully establish a SASP [131]. Thus, 
it might be tempting to suggest that an AMPK-induced 
energy crisis imposed by continuous exposure to 
metformin is a novel regulator of the DDR-SASP axis 
that reinforces the senescent phenotype.   
 
Two recent landmark studies [117, 132] help clarify the 
apparently counterintuitive pro-senescent activity of the 
anti-aging biguanide metformin [133-138]. Kang et al. 
[117] have confirmed that pre-malignant senescent 
hepatocytes secrete chemo- and cytokines and are 
subject to immune-mediated clearance (“senescence 
surveillance”) that strictly depends on an intact CD4+ 
T-cell-mediated adaptive immune response. 
Accordingly, impaired immune surveillance of pre-
malignant senescent hepatocytes results in the 
development of hepatocellular carcinomas, thus 
showing that senescence surveillance is important for 
tumor suppression in vivo by mounting specific immune 
responses against antigens expressed in pre-malignant 
senescent cells [117]. The molecular mechanisms 
presented here suggest that metformin’s use of the 
senescence program may significantly diminish the 
number of cells that can escape senescence. By 
activating the chemopreventive ATM-dependent DDR, 
metformin-treated cells might be sensitized for damage 
signaling, and metformin treatment might mimic the 
precancerous stimulus that generates a barrier against 
carcinogenesis. Because energy metabolism is being 
recognized as a/the critical pathway regulating the 
immortalization-to-senescence transition, metformin-
based therapies based on the induction of senescence 
would prevent the generation of CSCs. Concurrently, 
metformin treatment could lead to a significant 
alteration of “cancer immunoediting” (e.g., via 
restoration of MHC-related pathways) to impede tumor 
cell escape from immunosurveillance. The net effect of 
metformin treatment should be, therefore, a significant 
decrease in the accumulation of dysfunctional, pre-
malignant cells in tissues, including those with the 
ability to initiate tumors (i.e., CSCs).    
 
Whether senescent cells are causally implicated in age-
related dysfunction and whether their removal is 
beneficial have remained unknown until now. Baker et 
al. [132] have nicely answered this pivotal question by 
designing a transgenic strategy for the clearance of 
senescent cells in mice. Using a BubR1 progeroid 
mouse background designed for inducible elimination 
of p16
Ink4a-positive senescent cells, the authors 
demonstrate that in tissues in which p16
Ink4a contributes 
to the acquisition of age-related pathologies (i.e., 
adipose tissue, skeletal muscle and eye), life-long 
removal of p16
Ink4a-expressing cells significantly delays 
onset of these pathologies. Furthermore, late-life 
clearance notably attenuates progression of already 
established age-related disorders [132]. If metformin’s 
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barrier is accompanied by an enhanced clearance of pre-
malignant/tumor senescent cells, including those 
exhibiting tumor-initiating ability (i.e., CSCs), the net 
effect of the tissue sweeper functioning of metformin 
will be to halt the malignant/metastatic progression of 
pre-malignant/tumor senescent cells while preventing or 
delaying tissue dysfunction, thus extending the human 
lifespan. 
 
Note. In addition to SA-β-gal activity, senescence has 
been previously linked to induction of ROS production, 
which is believed to be necessary for maintenance of 
the senescence phenotype [139, 140]. ROS also play a 
pivotal role in promoting SA-β-gal activity following 
radiation-induced DNA damage. Accordingly, 
inhibition of ROS using N-acetyl cysteine (NAC) 
following radiation treatment drastically decreases 
senescence in tumor cells with normally high levels of 
radiation-induced SA-β-gal. In accordance with our 
current observations and taking advantage of earlier 
studies suggesting that metformin treatment induces 
ROS in certain cellular backgrounds [141], Skinner et al 
[142] have recently confirmed that enhanced rather than 
reduced ROS and SA-β-gal activity occurred when 
metformin was concurrently added to radiation in p53-
deficient tumor cells. Skinner’s findings that metformin 
treatment can overcome locoregional treatment failure 
in head and neck carcinomas by reinforcing the 
radiation-induced cellular senescence, which clinically 
translates into a significantly improved survival in 
patients taking metformin, strongly support our 
hypothesis that metformin’s ability to reinforce the 
establishment of accelerated senescence may function 
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